Have a feature idea you'd love to see implemented?
Let us know!
CRL Charles River Laboratories International Inc
Price (delayed)
$194.19
Market cap
$9.93B
P/E Ratio
24.12
Dividend/share
N/A
EPS
$8.05
Enterprise value
$12.48B
Charles River Laboratories, Inc., is an American corporation specializing in a variety of preclinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries. It also supplies assorted
Highlights
The price to earnings (P/E) is 22% lower than the 5-year quarterly average of 30.9 and 9% lower than the last 4 quarters average of 26.6
The equity is up by 14% year-on-year
The EPS fell by 13% YoY and by 4.3% QoQ
The net income has declined by 11% year-on-year and by 4% since the previous quarter
Key stats
What are the main financial stats of CRL
Market
Valuations
Earnings
Shares outstanding
51.14M
Market cap
$9.93B
Enterprise value
$12.48B
Price to earnings (P/E)
24.12
Price to book (P/B)
2.65
Price to sales (P/S)
2.46
EV/EBIT
19.32
EV/EBITDA
12.65
EV/Sales
3.07
Revenue
$4.06B
EBIT
$646M
EBITDA
$986.15M
Free cash flow
$560.48M
Per share
Balance sheet
Liquidity
EPS
$8.05
Free cash flow per share
$10.91
Book value per share
$73.26
Revenue per share
$79.02
TBVPS
$79.79
Total assets
$8B
Total liabilities
$4.18B
Debt
$2.76B
Equity
$3.78B
Working capital
$482.5M
Debt to equity
0.73
Current ratio
1.48
Quick ratio
0.95
Net debt/EBITDA
2.59
Margins
Efficiency
Dividend
EBITDA margin
24.3%
Gross margin
34.8%
Net margin
10.4%
Operating margin
13%
Return on assets
5.1%
Return on equity
11.2%
Return on invested capital
11%
Return on capital employed
9.2%
Return on sales
15.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRL stock price
How has the Charles River Laboratories International stock price performed over time
Intraday
3.35%
1 week
-1.38%
1 month
-0.44%
1 year
1.01%
YTD
-17.86%
QTD
-1.41%
Financial performance
How have Charles River Laboratories International's revenue and profit performed over time
Revenue
$4.06B
Gross profit
$1.41B
Operating income
$527.96M
Net income
$423.78M
Gross margin
34.8%
Net margin
10.4%
CRL's operating income is down by 19% YoY and by 6% QoQ
The operating margin fell by 16% YoY and by 6% QoQ
The net income has declined by 11% year-on-year and by 4% since the previous quarter
Charles River Laboratories International's net margin has decreased by 8% YoY and by 3.7% QoQ
Growth
What is Charles River Laboratories International's growth rate over time
Valuation
What is Charles River Laboratories International stock price valuation
P/E
24.12
P/B
2.65
P/S
2.46
EV/EBIT
19.32
EV/EBITDA
12.65
EV/Sales
3.07
The price to earnings (P/E) is 22% lower than the 5-year quarterly average of 30.9 and 9% lower than the last 4 quarters average of 26.6
The EPS fell by 13% YoY and by 4.3% QoQ
The price to book (P/B) is 45% lower than the 5-year quarterly average of 4.8 and 17% lower than the last 4 quarters average of 3.2
The equity is up by 14% year-on-year
The P/S is 30% lower than the 5-year quarterly average of 3.5 and 15% lower than the last 4 quarters average of 2.9
CRL's revenue is down by 3.7% year-on-year
Efficiency
How efficient is Charles River Laboratories International business performance
The ROE has contracted by 25% YoY and by 7% from the previous quarter
The company's return on assets fell by 18% YoY and by 6% QoQ
The company's return on invested capital fell by 17% YoY and by 4.3% QoQ
The ROS fell by 11% YoY and by 3.6% QoQ
Dividends
What is CRL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRL.
Financial health
How did Charles River Laboratories International financials performed over time
The company's total assets is 92% higher than its total liabilities
Charles River Laboratories International's current ratio has decreased by 6% from the previous quarter but it has increased by 2.1% YoY
The company's total assets rose by 5% YoY
Charles River Laboratories International's debt is 27% lower than its equity
Charles River Laboratories International's debt to equity has decreased by 17% YoY and by 3.9% from the previous quarter
The equity is up by 14% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.